BioClinica®, the world’s leading Medical Imaging service provider for clinical trials, and Alacrita, the transatlantic life science management consulting firm, announced today that Dr. Colin Miller has been appointed as Associate Partner at Alacrita. In his new role, Dr. Miller will be responsible for providing expert advice to the firm’s pharmaceutical and biotechnology clients, as well as overseeing a new partnership with BioClinica. Dr. Miller will continue to provide scientific support for major clinical trial imaging programs at BioClinica and will serve as Co-Chair of BioClinica’s Musculoskeletal Scientific Advisory Board.
Dr. Miller has made significant contributions to BioClinica’s growth for over two decades, as a leader of Medical Affairs and more recently as Vice President of Strategic Development. His scientific expertise and leadership has steered numerous clinical programs, forged successful collaborations with industry and academic partners, and identified key areas of expansion for BioClinica.
“This opportunity enables me to apply scientific acumen and technical insight I have garnered over the years at BioClinica to a broader range of companies seeking to thrive in the life sciences sector.” said Dr. Miller. “During this next phase of my career, I am pleased to continue a close relationship with my BioClinica colleagues and clients, while growing with Alacrita in new areas of clinical research.”
Dr. Miller brings with him a tremendous amount of industry experience, ambition, and enthusiasm for medical imaging. “His focused expertise in medical imaging and clinical trial design makes him an ideal addition to our high caliber consulting group” said Robert Johnson, Founding Partner at Alacrita. “As a world-class life science consulting firm, we fully support his commitment to BioClinica and the important clinical trials which they support.”
In his new post, Dr. Miller will continue to work closely with BioClinica’s Medical Imaging team and remains a critical driving force for BioClinica’s Musculoskeletal Scientific Advisory Board, designed to provide therapeutic area expertise for clinical trial sponsors developing new treatments.
“We are excited for Colin’s new role and the opportunity to foster a strategic partnership with Alacrita” said David Herron, Executive Vice President and President of BioClinica’s Medical Imaging, Cardiovascular Safety, and Molecular Markers business segment. “We look forward to our continued collaboration with Colin, leveraging his extensive scientific expertise and industry experience in support of our clients.”
Alacrita is a rapidly growing, transatlantic management consulting firm providing expertise-based services to the pharmaceutical, biotechnology and life science sectors. The firm is supported by an unrivalled team of experts who operate across the spectrum of life sciences. They combine extensive international industry experience (strategic, technical and commercial), broad functional capabilities and a track record of success across the industry.